

IPR2019-00207
Patent Owner Response

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC and AMNEAL
PHARMACEUTICALS OF NEW YORK, LLC

Petitioners

v.

ALMIRALL, LLC,

Patent Owner

Case IPR2019-00207
Patent 9,517,219

**PATENT OWNER'S RESPONSE TO
PETITION FOR *INTER PARTES* REVIEW**

TABLE OF CONTENTS

	<u>Page</u>
PATENT OWNER’S EXHIBIT LIST	v
I. INTRODUCTION	1
II. THE ’219 PATENT	3
III. SCOPE AND CONTENT OF THE PRIOR ART CONCERNING ACNE AND ROSACEA TREATMENTS	6
A. Acne.....	6
B. Prior Art Acne Treatments	9
1. First-Line Treatments.....	9
2. Combination Therapies	10
3. Emerging Treatments	13
C. Rosacea.....	14
IV. SCOPE AND CONTENT OF THE PRIOR ART CONCERNING DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS	15
A. Topical Dapsone for Treatment of Acne or Rosacea	15
B. Formulation of Topical Dapsone Products	18
C. Adapalene Combination Products	26
V. POSA	27
VI. CLAIM CONSTRUCTION	28
VII. THE PRIOR ART OF PETITIONERS’ GOUNDS DOES NOT RENDER OBVIOUS THE CHALLENGED CLAIMS OF THE ’219 PATENT	28

**TABLE OF CONTENTS
(Continued)**

	Page
A. A POSA Had No Genuine Reason to Treat Acne or Rosacea with a New Dapsone Topical Formulation	30
B. A POSA Would Not Reasonably Have Considered Garrett a Motivation to Make a New Topical Dapsone Formulation for Treatment of Acne or Rosacea	33
1. By 2012, a POSA Would Not Have Desired a Product Containing Undissolved Dapsone.....	33
2. Garrett Itself Teaches Dapsone Is Not Effective	39
3. Closer Art Teaches that Dapsone Is Not Effective	41
C. Petitioners Fail to Show Motivation to Increase Dapsone Concentration to the Claimed About 7.5%	43
D. The Prior Art Taught That Adapalene/Dapsone Combinations Were Superior to Dapsone-Only Topicals	45
E. No Motivation to Use the Claimed Polymeric Viscosity Builder.....	47
1. Petitioners Have Not Demonstrated A Credible Motivation to Combine with Nadau-Fourcade	51
2. Petitioners Have Not Demonstrated A Credible Motivation to Combine with Bonacucina.....	54
F. Neither Nadau-Fourcade Nor Bonacucina Teaches the Claimed Concentrations of Polymeric Viscosity Builder Comprising A/SA Copolymer for Use With the Dapsone Topical Formulations Allegedly Disclosed in Garrett.....	58
G. Objective Indicia of Non-Obviousness Further Support Denial of the Petition	60
VIII. CONCLUSION.....	64

TABLE OF AUTHORITIES

	Page(s)
CASES	
<i>Altana Pharma AG v. KUDCo</i> , No. 04-2355-JLL, 2010 WL 10804666 (D.N.J. Jul. 15, 2010)	42
<i>Altana Pharma AG v. Teva Pharm. USA, Inc.</i> , 566 F.3d 999 (Fed. Cir. 2009)	41
<i>Graham v. John Deere Co.</i> , 383 U.S. 1 (1966).....	29, 64
<i>Intelligent Bio-Sys., Inc. v. Illumina Cambridge Ltd.</i> , 821 F.3d 1359 (Fed. Cir. 2016)	29, 48
<i>Intendis GMBH v. Glenmark Pharms. Inc., USA</i> , 822 F.3d 1355 (Fed. Cir. 2016)	53
<i>KSR Int’l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	29
<i>Leo Pharm. Prods., Ltd. v. Rea</i> , 726 F.3d 1346 (Fed. Cir. 2013)	29
<i>Optivus Tech., Inc. v. Ion Beam Applications S.A.</i> , 469 F.3d 987 (Fed. Cir. 2006)	48
<i>Ortho-McNeil Pharm., Inc. v. Mylan Labs, Inc.</i> , 520 F.3d 1358 (Fed. Cir. 2008)	41
<i>Polaris Indus. Inc. v. Arctic Cat, Inc.</i> , 882 F.3d 1056 (Fed. Cir. 2018)	36
<i>Süd-Chemie, Inc. v. Multisorb Techs., Inc.</i> 554 F.3d 1001 (Fed. Cir. 2009)	46

**TABLE OF AUTHORITIES
(Continued)**

Page(s)

STATUTES AND RULES

35 U.S.C. § 316(e)28

OTHER AUTHORITIES

37 C.F.R. § 42.1(d)28

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.